KR20240156633A - 항-cd39 항체 및 이의 용도 - Google Patents

항-cd39 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240156633A
KR20240156633A KR1020247032745A KR20247032745A KR20240156633A KR 20240156633 A KR20240156633 A KR 20240156633A KR 1020247032745 A KR1020247032745 A KR 1020247032745A KR 20247032745 A KR20247032745 A KR 20247032745A KR 20240156633 A KR20240156633 A KR 20240156633A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032745A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 엘리자베스 바우먼
아다 페이 시안 첸
에스테르 페르난데즈-살라스
나이젤 펠럼 클린턴 워커
샤오닝 자오
야오화 후
시웨이 니에
지지에 구
Original Assignee
아르커스 바이오사이언시즈 인코포레이티드
우시 바이올로직스 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2022/079021 external-priority patent/WO2023164872A1/en
Application filed by 아르커스 바이오사이언시즈 인코포레이티드, 우시 바이올로직스 아일랜드 리미티드 filed Critical 아르커스 바이오사이언시즈 인코포레이티드
Publication of KR20240156633A publication Critical patent/KR20240156633A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247032745A 2022-03-03 2023-03-02 항-cd39 항체 및 이의 용도 Pending KR20240156633A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/079021 2022-03-03
PCT/CN2022/079021 WO2023164872A1 (en) 2022-03-03 2022-03-03 Anti-cd39 antibodies and use thereof
CN2022126070 2022-10-19
CNPCT/CN2022/126070 2022-10-19
PCT/CN2023/079295 WO2023165561A1 (en) 2022-03-03 2023-03-02 Anti-cd39 antibodies and use thereof

Publications (1)

Publication Number Publication Date
KR20240156633A true KR20240156633A (ko) 2024-10-30

Family

ID=87883061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032745A Pending KR20240156633A (ko) 2022-03-03 2023-03-02 항-cd39 항체 및 이의 용도

Country Status (13)

Country Link
US (2) US11970543B2 (https=)
EP (1) EP4486785A1 (https=)
JP (2) JP7712496B2 (https=)
KR (1) KR20240156633A (https=)
CN (2) CN119569881B (https=)
AR (1) AR128688A1 (https=)
AU (1) AU2023227964A1 (https=)
CA (1) CA3253669A1 (https=)
CL (1) CL2024002620A1 (https=)
IL (1) IL315351A (https=)
MX (1) MX2024010646A (https=)
TW (1) TW202340243A (https=)
WO (1) WO2023165561A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023402712A1 (en) * 2022-12-01 2025-05-08 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies
CN117986364B (zh) * 2023-12-27 2025-01-21 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3153526T3 (da) * 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
WO2016073845A1 (en) * 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
US20190071514A1 (en) 2016-03-14 2019-03-07 Innate Pharma Anti-cd39 antibodies
EP3452092B1 (en) 2016-05-06 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
IL316357A (en) 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019068907A1 (en) 2017-10-06 2019-04-11 Innate Pharma RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
SG11202002195YA (en) 2017-11-15 2020-04-29 Innate Pharma Potentiating the effect of atp release
MX394121B (es) 2018-03-14 2025-03-24 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos
KR20210031694A (ko) 2018-06-14 2021-03-22 베쓰 이스라엘 디코니스 메디칼 센터 인크 엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US20230242660A1 (en) 2019-02-21 2023-08-03 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
CN112714768B (zh) * 2019-08-27 2025-02-18 科望(苏州)生物医药科技有限公司 新型抗cd39抗体
US20220372160A1 (en) 2019-09-16 2022-11-24 Surface Oncology, Inc. Anti-CD39 Antibody Compositions and Methods
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
CN114651013B (zh) 2019-11-05 2025-03-14 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
WO2021203058A2 (en) 2020-04-03 2021-10-07 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
KR20230065974A (ko) 2020-09-10 2023-05-12 퓨리노미아 바이오테크, 아이엔씨. NTPDase3의 표적화를 통해 항종양 면역 반응을 강화하기 위한 방법 및 조성물
US20230416394A1 (en) 2020-11-27 2023-12-28 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta

Also Published As

Publication number Publication date
JP2025148452A (ja) 2025-10-07
JP2025508956A (ja) 2025-04-10
AU2023227964A1 (en) 2024-09-19
IL315351A (en) 2024-11-01
EP4486785A1 (en) 2025-01-08
CA3253669A1 (en) 2023-09-07
WO2023165561A1 (en) 2023-09-07
MX2024010646A (es) 2024-09-19
US11970543B2 (en) 2024-04-30
CN119569881A (zh) 2025-03-07
US20240034803A1 (en) 2024-02-01
CN119569881B (zh) 2025-11-07
CN119173535A (zh) 2024-12-20
CL2024002620A1 (es) 2025-01-03
JP7712496B2 (ja) 2025-07-23
AR128688A1 (es) 2024-06-05
US20250084178A1 (en) 2025-03-13
TW202340243A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
US11820824B2 (en) Antibodies to TIGIT
EP3471753B1 (en) Anti-pd-l1 and il-2 cytokines
TWI719970B (zh) 針對ｉｃｏｓ之抗體
JP2020180135A (ja) 抗ｐｄ−ｌ１抗体およびその使用
EP3617232A1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3966242A1 (en) Cd123-binding polypeptides and uses thereof
US11970543B2 (en) Anti-CD39 antibodies and use thereof
BR112018010410A2 (en) method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells
US20230054718A1 (en) Anti-galectin-9 antibody and uses thereof
US20250179176A1 (en) Anti-tigit antibodies and uses of the same
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
US20240158517A1 (en) Anti-human cxcr5 antibody and uses thereof
HK40113788A (zh) 抗cd39抗体及其用途
WO2021091960A1 (en) Methods of treating cancer with anti-pd-1 antibodies
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40122875A (zh) 抗tigit抗体及其用途
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies
HK40014488A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000